<DOC>
	<DOCNO>NCT01242917</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , Phase 2 study evaluate safety efficacy CCX354-C subject rheumatoid arthritis partially responsive methotrexate therapy .</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy CCX354-C Subjects With Rheumatoid Arthritis Partially Responsive Methotrexate Therapy</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>1 . Male female subject , age 1875 year inclusive , functional class I III rheumatoid arthritis ( RA ) base American College Rheumatology ( ACR ) criteria least 3 month prior screen ; wheelchair bound subject irreversible disease eligible ; 2 . Subjects must active RA , define minimum 8 swollen joint 8 tender/painful joint ( base 66/68 joint count ) , screen 3 . Serum Creactive protein ( CRP ) 5 mg/L screening ; 4 . Must methotrexate ( 7.5 25 mg/week ) take orally , subcutaneously , intramuscularly ≥ 16 week stable dose ≥ 8 week prior randomization ; 5 . If hydroxychloroquine , must stable dose ≥ 16 week prior randomization ; 6 . If take nonsteroidal antiinflammatory drug ( NSAIDs ) , must stable dos ≥ 2 week randomization ; 7 . If take oral corticosteroid , subject may take 10 mg/day prednisone equivalent , must stable dose ≥ 4 week randomization ; 8 . Willing able give write Informed Consent comply requirement study protocol ; 9 . Negative result human immunodeficiency virus ( HIV ) screen , hepatitis B screen , hepatitis C screen ; 10 . Judged otherwise healthy Investigator , base medical history , physical examination ( include electrocardiogram [ ECG ] ) , clinical laboratory assessment ; 11 . Female subject childbearing potential , male subject partner childbearing potential , may participate adequate contraception use , least four week administration study medication 1 . Diagnosed RA prior 16 year age ; 2 . Women pregnant , breastfeeding , positive serum pregnancy test screening ; 3 . History within one year prior randomization illicit drug use ; 4 . History alcohol abuse time past ; 5 . Have receive sulfasalazine , azathioprine , 6mercaptopurine , mycophenolate mofetil , tetracycline , cyclosporine , gold , tacrolimus , sirolimus , disease modify antirheumatic drug ( DMARD ) within 8 week randomization ; 6 . Use infliximab , adalimumab , abatacept , certolizumab , golimumab , tocilizumab within 8 week randomization ; 7 . Use leflunomide within 6 month randomization ; 8 . Use etanercept anakinra within 4 week randomization ; 9 . Use Bcell deplete agent rituximab ocrelizumab , cytotoxic agent , cyclophosphamide chlorambucil , within one year randomization ; 10 . Currently take cytochrome P450 inhibitor include protease inhibitor ritonavir , indinavir , nelfinavir , macrolide antibiotic erythromycin , telithromycin , clarithromycin , azole antifungal fluconazole , ketoconazole , itraconazole , cimetidine , nefazodone , bergamottin ( constituent grapefruit juice ) , quercetin , aprepitant , verapamil ; 11 . Currently take cytochrome P450 inducer include St. John 's wort , rifampicin , rifabutin , rifapentin , dexamethasone , phenytoin , carbamazapine , phenobarbitol , troglitazone ; 12 . Intraarticular , intravenous , intramuscular corticosteroid injection within 4 week randomization ; 13 . History presence form cancer within 10 year prior randomization , exception excise basal cell squamous cell carcinoma skin , cervical carcinoma situ breast carcinoma situ excise resect completely without evidence local recurrence metastasis ; 14 . Evidence tuberculosis ( TB ) base chest X ray , tuberculin skin test , QuantiFERON®TB Gold test , TSPOT® . 15 . Presence Felty 's syndrome , psoriatic arthritis , gout , autoimmune disease ; 16 . Major surgery ( include joint surgery ) within 12 week prior randomization ; 17 . The subject infection require antibiotic treatment within 4 week randomization ; 18 . Subject evidence hepatic disease ; Aspartate Aminotransferase ( AST ) , Alanine Aminotransferase ( ALT ) , alkaline phosphatase , bilirubin &gt; 1.5 x upper limit normal ; 19 . Subject evidence renal impairment ; serum creatinine &gt; 1.5 x upper limit normal estimate Glomerular Filtration Rate ( GFR ) base CockcroftGault equation &lt; 30 mL/min ; 20 . History presence medical psychiatric condition disease , laboratory abnormality , opinion Investigator , may place subject unacceptable risk study participation may prevent subject complete study 21 . Participated clinical study investigational product include CCX354C within 30 day 5 time half life agent , whichever longer , prior randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>